Bogowicz, Marta http://orcid.org/0000-0002-4747-5375
Jochems, Arthur
Deist, Timo M.
Tanadini-Lang, Stephanie
Huang, Shao Hui http://orcid.org/0000-0002-8072-4388
Chan, Biu
Waldron, John N.
Bratman, Scott http://orcid.org/0000-0001-8610-4908
O’Sullivan, Brian
Riesterer, Oliver
Studer, Gabriela
Unkelbach, Jan
Barakat, Samir
Brakenhoff, Ruud H.
Nauta, Irene
Gazzani, Silvia E.
Calareso, Giuseppina
Scheckenbach, Kathrin
Hoebers, Frank
Wesseling, Frederik W. R.
Keek, Simon
Sanduleanu, Sebastian
Leijenaar, Ralph T. H.
Vergeer, Marije R.
Leemans, C. René
Terhaard, Chris H. J.
van den Brekel, Michiel W. M.
Hamming-Vrieze, Olga
van der Heijden, Martijn A.
Elhalawani, Hesham M. http://orcid.org/0000-0001-9848-2623
Fuller, Clifton D. http://orcid.org/0000-0002-5264-3994
Guckenberger, Matthias
Lambin, Philippe http://orcid.org/0000-0002-9034-0177
Article History
Received: 3 April 2019
Accepted: 28 January 2020
First Online: 11 March 2020
Competing interests
: Dr. Lambin reports grants/sponsored research from Oncoradiomics SA, ptTheragnostic, advisor (SAB)/presentor fee from Oncoradiomics SA. Dr. Lambin is inventor of two patents on radiomics and one non patentable invention (softwares), licensed to Oncoradiomics SA and has (minority) shares in the company Oncoradiomics SA. Dr. Jochems has (minority) shares in the company Oncoradiomics SA. Dr. Barakat is an employee of ptTheragnostic and Oncoradiomics SA. Dr. Leijenaar has shares in, and is Chief Technology Officer of, the company Oncoradioomics SA. He is co-inventor of an issued patent with royalties related to radiomics (PTC/NL2014/050728) licensed to Oncoradiomics. Dr. Bogowicz, Dr. Deist, Dr. Tanadini-Lang, Dr. Huang, Dr. Chan, Dr. Waldron, Dr. Bratman, Dr. O’Sullivan, Dr. Riesterer, Dr. Studer, Dr. Unkelbach, Dr. Brakenhoff, Dr. Nauta, Dr. Gazzani, Dr. Calareso, Dr. Scheckenbach, Dr. Hoebers, Dr. Wesseling, Dr. Keek, Dr. Sanduleanu, Dr. Vergeer, Dr. Leemans, Dr. Terhaard, Dr. van den Brekel, Dr. Hamming-Vrieze, and Dr. van der Heijden, Dr. Elhalawani, Dr. Fuller and Dr. Guckenberger declare no potential conflict of interest.